Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective

doi:10.1111/dom.14205

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 其他文獻 > Item 310902500/25057

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/25057

Title:	Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective
Authors:	Ji, LN;Chan, JCN;Yu, M;Yoon, KH;Kim, SG;Choi, SH;Huang, CN;Te Tu, S;Wang, CY;Paldanius, PM;Sheu, WHH
Keywords:	antidiabetic drug;beta-cell function;metformin;type 2 diabetes;vildagliptin
Date:	2021
Issue Date:	2022-08-09T09:27:44Z (UTC)
Publisher:	WILEY
ISSN:	1462-8902
Abstract:	Type 2 diabetes (T2D) in the East Asian population is characterized by phenotypes such as low body mass index, an index of beta-cell dysfunction, and higher percentage of body fat, an index of insulin resistance. These phenotypes/pathologies may predispose people to early onset of diabetes with increased risk of stroke and renal disease. Less than 50% of patients with T2D in East Asia achieve glycaemic targets recommended by national or regional guidelines, which may be attributable to knowledge and/or implementation gaps. Herein, we review the latest evidence with special reference to East Asian patients with T2D and present arguments for the need to use early combination therapy to intensify glycaemic control. This strategy is supported by the 5-year worldwide VERIFY study, which reported better glycaemic durability in newly diagnosed patients with T2D with a mean HbA1c of 6.9% treated with early combination therapy of vildagliptin plus metformin versus those treated with initial metformin monotherapy followed by addition of vildagliptin only with worsening glycaemic control. This paradigm shift of early intensified treatment is now recommended by the American Diabetes Association and the European Association for the Study of Diabetes. In order to translate these evidence to practice, increased awareness and strengthening of the healthcare system are needed to diagnose and manage patients with T2D early for combination therapy.
URI:	http://dx.doi.org/10.1111/dom.14205 https://www.webofscience.com/wos/woscc/full-record/WOS:000587400500001 https://ir.csmu.edu.tw:8080/handle/310902500/25057
Relation:	DIABETES OBESITY & METABOLISM ,2021 ,v23 ,issue 1 ,p3-17
Appears in Collections:	[中山醫學大學研究成果] 其他文獻

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	255	View/Open

Loading...